2016 VAM: 1802 - Management of Atopic Dermatitis: What's New?
The course discusses possible therapeutic consequences owing to new insights into the pathogenesis of atopic dermatitis.
AMA PRA Category 1 Credits™: 1.25
Credit must be claimed by May 31, 2018. Any credit request on or after June 1, 2018 will be subject to an administrative fee.
Allied Health Professionals
Upon completion of this session, participants should be able to:
1. Discuss the role of skin microbiome in atopic dermatitis
2. Discuss patient education for atopic dermatitis
3. Discuss possible therapeutic consequences owing to new insights into the pathogenesis of atopic dermatitis
Lisa A. Beck, MD FAAAAI, University of Rochester Medical Center, Rochester, NY
Relevant relationships: Consultant Abbvie (Ongoing): Array Biopharma (Ongoing): Celgene (Ongoing): Janssen (Ongoing): Medimmune (Ongoing): Novartis (Ongoing): Regeneron (Ongoing): Unilever. Wyeth (Ongoing): Stocks
Donald Y.M. Leung, MD PhD FAAAAI, National Jewish Health, Denver, CO
Relevant relationships: Advisory Board: Biogen-Idec, Celgene, GSK, Galderma, Novartis, Regeneron, Sanofi.
Dagmar Simon, MD, University Hospital Bern, Bern, Switzerland
Relevant relationships: None
Annual Meeting sessions and faculty were reviewed by members of the Practice Improvement Subcommittee. Disclosures are located in the 2016 Annual Meeting Disclosures PDF.
- 1.25 AttendanceAttendance credit.
- 1.25 CECE credit.
- 1.25 CMECME credit.